Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer
暂无分享,去创建一个
C. Annunziata | Carrie Danielle House | Lidia Hernandez | Christina Messineo Annunziata | C. House | L. Hernandez
[1] Raphael Kopan,et al. Real-Time Imaging of Notch Activation with a Luciferase Complementation-Based Reporter , 2011, Science Signaling.
[2] G. Freeman,et al. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. , 2013, Cancer research.
[3] A. Skubitz,et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. , 2013, Gynecologic oncology.
[4] G. Enikolopov,et al. Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.
[5] G. Luker,et al. Imaging CXCL12-CXCR4 Signaling in Ovarian Cancer Therapy , 2013, PloS one.
[6] D. Levine,et al. Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen , 2010, Clinical Cancer Research.
[7] R. Drapkin,et al. Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms , 2013, Front. Oncol..
[8] J. Schorge,et al. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. , 2011, Frontiers in bioscience.
[9] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[10] X. Ye,et al. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer. , 2013, International journal of molecular medicine.
[11] G. Luker,et al. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. , 2011, Neoplasia.
[12] M. Broggini,et al. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. , 2013, Cancer treatment reviews.
[13] Tao Zhang,et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.
[14] D. Matei,et al. Epithelial ovarian cancer experimental models , 2014, Oncogene.
[15] K. Garber. From human to mouse and back: 'tumorgraft' models surge in popularity. , 2009, Journal of the National Cancer Institute.
[16] K. Sugamura,et al. Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging. , 2009, Luminescence : the journal of biological and chemical luminescence.
[17] I. Dick,et al. Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.
[18] Robert M Hoffman,et al. The challenges posed by cancer heterogeneity , 2012, Nature Biotechnology.
[19] Andrew J. Wilson,et al. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model , 2013, Journal of Ovarian Research.
[20] P. Bitterman,et al. Detection of Tumor‐Associated Neoangiogenesis by Doppler Ultrasonography During Early‐Stage Ovarian Cancer in Laying Hens , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[21] J. Plowman,et al. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. , 1990, Cancer treatment reviews.
[22] H. Varmus,et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. , 2002, Cancer cell.
[23] L. D. White,et al. Molecular and Functional Characteristics of Ovarian Surface Epithelial Cells Transformed by KrasG12D and loss of Pten in a Mouse Model in vivo , 2011, Oncogene.
[24] D. Xing,et al. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. , 2006, Cancer research.
[25] M. Neeman,et al. Ovarian carcinoma: quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors. , 2013, Radiology.
[26] M. Sehested,et al. [18F]FLT PET for Non-Invasive Assessment of Tumor Sensitivity to Chemotherapy: Studies with Experimental Chemotherapy TP202377 in Human Cancer Xenografts in Mice , 2012, PloS one.
[27] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Hagemann,et al. Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis , 2007, Molecular Cancer Therapeutics.
[29] Y. Bignon,et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). , 2000, International journal of oncology.
[30] C. Molthoff,et al. Human ovarian cancer xenografts in nude mice: Characterization and analysis of antigen expression , 1991, International journal of cancer.
[31] G. Vassaux,et al. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. , 2011, Vaccine.
[32] Jay A. Berzofsky,et al. NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.
[33] David A. Tuveson,et al. The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics , 2006, Clinical Cancer Research.
[34] A. Flesken-Nikitin,et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.
[35] Annie Y. Liu,et al. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. , 2012, International journal of clinical and experimental pathology.
[36] R. Hoffman,et al. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. , 1993, Anticancer research.
[37] J. Tanyi,et al. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. , 2012, Immunotherapy.
[38] R. Brentjens,et al. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. , 2010, Discovery medicine.
[39] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[40] Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures , 2013, BMC Cell Biology.
[41] R. Buckanovich,et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. , 2012, Gynecologic oncology.
[42] O. Fiehn,et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.
[43] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[44] M. Banerjee,et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells , 2012, International journal of cancer.
[45] P. Shaw,et al. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. , 2008, Gynecologic oncology.
[46] R. Hruban,et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.
[47] G. Freeman,et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.
[48] Stephen J. Williams,et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer , 2007, Cancer biology & therapy.
[49] M. Anderson,et al. Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer1 , 2007, The Journal of Immunology.
[50] C. Peterson,et al. Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model. , 2013, Anticancer research.
[51] H. Piwnica-Worms,et al. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[52] J. Haselden,et al. Metabolic Profiling as a Tool for Understanding Mechanisms of Toxicity , 2008, Toxicologic pathology.
[53] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[54] Jean-François Ethier,et al. Reproductive Biology and Endocrinology Open Access Animal Models of Ovarian Cancer , 2022 .
[55] D. Redelmeier,et al. Translation of research evidence from animals to humans. , 2006, JAMA.
[56] M. Pisanu,et al. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion‐weighted imaging , 2012, NMR in biomedicine.
[57] B. Teicher. Tumor Models in Cancer Research , 2001, Cancer Drug Discovery and Development.
[58] T. Orfeo,et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.
[59] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[60] Colleen A Crane,et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[61] R. Puri,et al. IL‐13 regulates cancer invasion and metastasis through IL‐13Rα2 via ERK/AP‐1 pathway in mouse model of human ovarian cancer , 2012, International journal of cancer.
[62] D. Huntsman,et al. Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[63] M. Yi,et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. , 2012, Cancer research.
[64] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[65] R. Buckanovich,et al. Ovarian cancer stem cells: working towards the root of stemness. , 2013, Cancer letters.
[66] A. Godwin,et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.
[67] N. Yang,et al. Animal Model Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma , 2002 .
[68] S. Litwin,et al. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. , 2012, Neoplasia.
[69] A. Godwin,et al. Genetics and ovarian carcinoma. , 1998, Seminars in oncology.
[70] A. Gibson,et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.
[71] A. Welm,et al. Overview of Human Primary Tumorgraft Models: Comparisons with Traditional Oncology Preclinical Models and the Clinical Relevance and Utility of Primary Tumorgrafts in Basic and Translational Oncology Research , 2012, Current protocols in pharmacology.
[72] M. Piver,et al. Characterization of human ovarian carcinomas in a SCID mouse model. , 1999, Gynecologic oncology.
[73] L. Seymour,et al. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] D. Huntsman,et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. , 2005, Gynecologic oncology.
[75] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[76] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[77] Yasuyoshi Watanabe,et al. [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.
[78] J L Pace,et al. Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.
[79] Rodney J Hicks,et al. In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.
[80] M. Hendrix,et al. A Model of Cancer Stem Cells Derived from Mouse Induced Pluripotent Stem Cells , 2012, PloS one.
[81] R. Chen,et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.
[82] M. Dimopoulos,et al. Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization , 2011, Clinical & developmental immunology.
[83] R. Kurman,et al. Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the Ovary: A Clinicopathologic Analysis of 135 Cases , 2003, The American journal of surgical pathology.
[84] X. Hua,et al. Development of a syngeneic mouse model of epithelial ovarian cancer , 2010, Journal of ovarian research.
[85] S. Gambhir,et al. Non-Invasive Imaging of Phosphoinositide-3-Kinase-Catalytic-Subunit-Alpha (PIK3CA) Promoter Modulation in Small Animal Models , 2013, PloS one.
[86] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[87] F. Schmidt. Meta-Analysis , 2008 .
[88] Denise G. Lanza,et al. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model , 2012, Tumor Biology.
[89] Sham S. Kakar,et al. Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer , 2011, PloS one.
[90] R. L. Baldwin,et al. A human ovarian carcinoma murine xenograft model useful for preclinical trials. , 2002, Gynecologic oncology.